The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Emily Reeve1,2
- Barbara Farrell3,4
- Wade Thompson5
- Nathan Herrmann6,7
- Ingrid Sketris8
- Parker J Magin9,10
- Lynn Chenoweth11,12
- Mary Gorman8,13
- Lyntara Quirke14,15
- Graeme Bethune16
- Sarah N Hilmer1,17
- 1 NHMRC Cognitive Decline Partnership Centre, Kolling Institute of Medical Research, Northern Clinical School, University of Sydney, Sydney, NSW
- 2 Dalhousie University and Nova Scotia Health Authority, Halifax, Canada
- 3 Bruyère Research Institute, Ottawa, Canada
- 4 University of Ottawa, Ottawa, Canada
- 5 University of Southern Denmark, Odense, Denmark
- 6 Sunnybrook Health Sciences Centre, Toronto, Canada
- 7 University of Toronto, Toronto, Canada
- 8 Dalhousie University, Halifax, Canada
- 9 University of Newcastle, Newcastle, NSW
- 10 NSW and ACT Research and Evaluation Unit, GP Synergy Regional Training Organisation, Sydney, NSW
- 11 Centre for Healthy Brain Ageing, UNSW, Sydney, NSW
- 12 University of Notre Dame, Sydney, NSW
- 13 St Martha's Regional Hospital, Antigonish, Canada
- 14 Consumer Network, Alzheimer's Australia, Canberra, ACT
- 15 Dementia Training Australia
- 16 Nova Scotia Health Authority, Halifax, Canada
- 17 Royal North Shore Hospital and University of Sydney, Sydney, NSW
Funding:
The guideline development, publication, dissemination and implementation were funded through an NHMRC‐ARC Dementia Research Development Fellowship awarded to Emily Reeve (APP1105777). The funding body had no involvement in guideline development and, as such, the views and/or interests of the funding body have not influenced the final recommendations.
We thank Lisa Kouladjian O'Donnell, Judith Godin, Caitlin Lees, Emma Squires, Ivanka Hendrix and Robin Parker, who contributed to the systematic review which informed the development of the guideline.
Emily Reeve has received support to attend conferences to present work related to deprescribing by the NHMRC Cognitive Decline Partnership Centre, Canadian Frailty Network, TUTOR‐PHC Program (Western University), University of Sydney Medical School, Ramsay Research and Teaching Fund (Kolling Institute Travel Award, Royal North Shore Hospital Scientific Staff Council), Swiss Society of Internal Medicine and the Pharmacy Association of Nova Scotia; has received prize money from Bupa Health Foundation; and has received grants from the Canadian Frailty Network, CC‐ABHI Knowledge Mobilisation Partnership Program and the US National Institutes of Health for work related to deprescribing. Barbara Farrell has received consultancy fees and grants (including reimbursement for travel for research meetings or education sessions) from the Institute for Healthcare Improvement, College of Psychiatric and Neurologic Pharmacists, European Association of Hospital Pharmacists, Nova Scotia College of Pharmacists, Canadian Society of Hospital Pharmacists, and Ontario Pharmacists Association; and has received research grants from the Canadian Foundation for Pharmacy, Centre for Aging Brain Health and Innovation, Canadian Institute of Health Research, and Ontario Ministry of Health and Long‐Term Care for work related to deprescribing. Wade Thompson received a Master of Science stipend from government of Ontario for work on deprescribing, and speaking fees to present at conferences on deprescribing from the Advanced Learning in Palliative Medicine Conference, Ontario Long‐Term Care Clinicians Conference, and Geriatrics in Primary Care conference (University of Ottawa). Nathan Herrmann has received consultancy fees for dementia drug development from Lilly, Astellas and Merck; grants from Lundbeck and Roche for dementia investigational drug trials; and support from the Canadian Consortium on Neurodegeneration in Aging (CCNA) funded by the Canadian Institute of Health Research and several partners. Ingrid Sketris receives a partial salary stipend from Canadian Institute of Health Research (CIHR) as part of the Canadian Network for Observational Effect Studies and has received grants from CIHR (including funds utilized to present research results) and the Nova Scotia Department of Health and Wellness. Parker Magin has received grants from the Judith Jane Mason & Harold Stannett Williams Memorial Foundation Medical Program Grants, and the Royal Australian College of General Practitioners: Education Research Grant for potentially related work. Sarah Hilmer has received funding from the NHMRC Cognitive Decline Partnership Centre to support work related to deprescribing in people with dementia.
Abstract
Introduction: Cholinesterase inhibitors (ChEIs) and memantine are medications used to treat the symptoms of specific types of dementia. Their benefits and harms can change over time, particularly during long term use. Therefore, appropriate use of ChEIs and memantine involves both prescribing these medications to individuals who are likely to benefit, and deprescribing (withdrawing) them from individuals when the risks outweigh the benefits. We recently developed an evidence‐based clinical practice guideline for deprescribing ChEIs and memantine, using robust international guideline development processes.
Main recommendations: Our recommendations aim to assist clinicians to:
Changes in management as a result of the guideline: